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Summary: Scaling up of antiretroviral treatment (ART) for children in countries like
Thailand will require decentralization and management by non-specialist doctors.
We describe (a) the formulation of a standardized drug dosage table to facilitate
antiretroviral drug (ARV) prescriptions for children, (b) the acceptability of such a
table among doctors and (c) the safety and efﬁcacy of drug doses in the table.
Acceptability was assessed using a questionnaire. Safety and efﬁcacy were
assessed on the basis of incidence of adverse effects and virological response to
treatment, respectively.
Of all doctors (n¼18), 17 (94%) found that the table was practical to use, avoided
miscalculations and made them more conﬁdent with prescriptions. Of 49 children
prescribed ARVs, less than 5% had adverse side-effects. All ARV-naı ¨ve children
achieved undetectable viral loads within six months of ART.
In our setting, a standardized drug dosage table provided a simple and reliable
tool that facilitated ARV prescriptions for children.
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Introduction
In 2001, the Thai Ministry of Public Health began
offering highly active antiretroviral treatment
(HAART) to children with HIV/AIDS in Thailand.
The programme eventually aims to reach all of the
estimated 21,000 children
1 with HIV/AIDS need-
ing HAART. In order to achieve this, there will be a
need to decentralize treatment to district hospitals
where non-specialists will have to prescribe
HAART.
A number of obstacles hamper this process.
  Doctors at district level, inexperienced with
prescribing HAART, lack conﬁdence due to
unfamiliar and complex dose expressions. Drug
dosages are expressed in terms of body surface
area for some drugs, but by body weight for
others. Dosage calculations become time-con-
suming and with a high-patient load, prone to
human error. Mistakes also often occur in the
measurement of children’s height.
  International
2–4 and Thai
5 recommendations
give broad and inconsistent dosage ranges for
some antiretroviral (ARV) drugs, which thus
appear vague (Table 1). Standardization of
prescriptions thus becomes difﬁcult.
  Paediatric syrup formulations where available
are expensive, have a short shelf-life, and are
difﬁcult to store. Available syrups are also
generally of low concentration and thus chil-
dren have to swallow large volumes of un-
palatable liquid, which often induces vomiting.
For example: a child weighing 12kg and on a
triple therapy regimen of zidovudine (AZT),
lamivudine (3TC) and nevirapine (NVP) would
need to swallow a total of 27.5mL (12.5mL of
AZT, 5mL of 3TC and 10mL of NVP) of syrup
twice daily. Many caretakers of children are old
and illiterate and cannot measure such different
volumes of different syrups. Many even ask for
capsules or tablets which are easier to manage
than syrups. These are also less obvious when
being carried home. Tablets or capsules are,
however, rarely available in paediatric dosages.
  In practice, unrealistic prescriptions for
children are written, based on fractions of
adult tablet formulations. Examples of required
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6 are given in Table 2. Parents
or caretakers cannot accurately break off such
fractions of a tablet or open capsules to dissolve
a prescribed portion of the powder. Further-
more, some tablets such as Epivir
s (3TC)
tablets are not scored and breaking off fractions
of such tablets accurately is difﬁcult. Moreover,
the effect of breaking tablets, not designed to be
broken, or of opening capsules on bioavail-
ability is unknown. Thus, achieving accurate
dosing for children is often impossible in
practice.
  Once children start antiretroviral treatment
(ART), weight gain necessitates ongoing dosage
adjustment. Fine tuning of such adjustments is
impossible due to the limited range of available
formulations and seems irrelevant, considering
the wide ranges of currently recommended
dosages.
2–5 Moreover, blood levels of some
drugs depend less on weight or body surface
than on genetic factors (nevirapine [NVP]) and
renal clearance (lamivudine [3TC] and stavu-
dine [D4T]).
ARV prescriptions for children in resource-poor
settings need to be simpliﬁed and made more user-
friendly. In our setting, a standardized drug dosage
table provided a simple and reliable tool to
facilitate prescriptions among paediatricians and
general practitioners (GPs). This report gives an
overview of the drug dosage table in terms of (a)
how it was formulated, (b) its acceptability among
doctors and (c) safety and efﬁcacy of doses in the
table.
Materials and methods
Setting
The drug dosage table has been used since
February 2002 in one provincial hospital
(PraChomklao) and two district hospitals (Ban
Laem and Kuchinarai hospitals). These hospitals
started HAART in children with the support of a
non-governmental organization (Me ´decins sans
Frontieres [MSF]).
The standard ﬁrst-line triple regimen for children
was zidovudine (AZT)/3TC/NVP. In case of severe
adverse drug reactions to AZT or NVP, these were
replaced with D4T or efavirenz (EFV), respectively.
The standard second-line ARVregimen for children
was a combination of D4T, didanosine (DD1) and
nelﬁnavir (NFV). The regimens for experienced
children were individualized.
All ARV drugs were registered in Thailand. EFV
and nelﬁnavir were originator brand products,
while all the others were generics produced by
the Government Pharmaceutical Organization
(GPO). The choice of drugs and regimens was in
accordance with Thai national guidelines.
5
The drug dosage table
Formulation of the drug dosage table in 2001, and a
2003 revision, took into account international
2–4
and Thai
5 dosage guidelines and the availability of
drug formulations. The upper and lower values of
recommended dosages for ARV drugs available in
Thailand were expressed for body weight ranges of
5kg for children weighing up to 30kg, and for
ranges of 10kg for adolescents and adults weighing
up to 60kg. Where different guidelines recom-
mended different dosages, we chose the median
recommended dose. This is the case with AZT
(Table 1).
For drugs where dosage is based on body surface
area, the maximum height for the upper value of
each weight range and the minimum height for the
lower value were derived from existing growth
charts of children in Thailand
7 (allowing for a
standard deviation of  1.5 to þ1.5). Upper and
lower limits of surface area were then calculated
for each weight range using Mosteller’s formula.
8
The upper and lower doses for each weight range
were then easily determined and a feasible dosage
between these limits was included in the table.
Because of lack of paediatric formulations, or in
order to include a feasible dosage in the table, some
drugs are relatively over or under dosed in the
table in some weight ranges. For example, in the
case of NVP, for children weighing between 15 and
19kg, using WHO
2 and PENTA
3 guidelines would
result in a dose of 150mg twice daily. Using tablet
formulations, we chose to include a dose of half a
tablet (100mg) twice daily, below the median
recommended dosage, but still within the range
recommended by the American Paediatric Guide-
lines
4 and also by Boehringer Ingelheim.
To facilitate drug administration, the dosages
were expressed as either half or whole tablets or in
the case of syrups as half (2.5mL) or whole (5mL)
medicine spoonfuls. In our experience, elderly
caretakers cannot be expected to break smaller
proportions of tablets or use syringes. We generally
expressed doses as once or twice daily, avoiding
three times a day dosing. Some boosted protease
inhibitor dosages are not included in international
Table 1 Recommended paediatric dosage for zidovudine (AZT)
180mg per m
2 of body surface area every 12h
2,3
90mg per m
2 of body surface area to 180 per m
2 of body surface
area every 6–8h
4
160mg per m
2 of body surface area every 8h
5
Table 2 Examples of recommended antiretroviral dosages
expressed as fractions of tablet formulations
6
Child 3–4kg: Child 10kg:
3TC 1/10 tablet BID AZT 3
4 Caps BID
d4T: 1/8 tablet BID 3TC: 1
4 tablet BID
NVP: 2.5–4mL BID NVP: 5.5–9mL BID
BID=twice daily; 3TC=lamivudine; d4T=stavudine; NVP=nelﬁnavir; AZT=zidovudine
Ponnet et al. A drug dosage table facilitates ARV prescriptions 421guidelines. For these we used evidence from
pharmacokinetic studies.
9,10 The table does not
include dosages for small infants as we feel that
clinical management of neonates should be the
responsibility of specialists.
Acceptability among doctors
A structured questionnaire that was pre-tested was
used to gather information on the use of the drug
dosage table among all doctors working in the
PraChomKlao hospital in October 2003. This
hospital was chosen for the survey as most children
on ART are being followed up here. The hospital
also has the largest numbers of doctors including
several GPs. A questionnaire was given to the
doctors 10 months after the ARV table was
introduced.
Speciﬁc information that was sought included
whether or not the table was simple to understand,
practical to use, helped avoid miscalculations of
doses and whether it facilitated ARV prescriptions.
The responses were ﬁlled up in an anonymous
manner and analysed using the SPSS software
(SPSS Inc., Chicago, IL 60606, USA).
Safety and efﬁcacy of drug doses
All children placed on ARVs were followed up on a
two-weekly basis for the ﬁrst month, then on a
monthly basis thereafter. Children were monitored
for adverse side-effects at each follow-up visit and
these were recorded on the patient ﬁle. Care-takers
(and children who were old enough to understand)
were made aware of the potential side-effects of
drugs contained in a particular HAART regimen
and were asked about the side-effects on each
follow-up visit. A systematic physical examination
was also conducted. A list of known side-effects
was made available to all clinicians, who were
required on a systematic basis to enquire about the
presence or absence of a known side-effect. All
children had a full blood count (including haemo-
globin) and a liver function test (ALAT) done at
baseline and then on a monthly basis in order to
monitor AZT-induced anaemia and the develop-
ment of hepatitis, respectively. Serum creatinine
and amylase were also assessed at baseline and
subsequently every 12 months. Clinicians could
also request additional laboratory investigations on
the basis of clinical suspicion of side-effects.
Additional information on side-effects was ob-
tained through counsellors and nurses who made
home visits between scheduled clinic visits. A
protocol for the management of adverse side-
effects was available and both the medical and
support team were trained on its recognition and
management. We used the incidence of adverse
drug reactions to assess safety of drug doses
prescribed using the dosage table.
CD4 levels were assessed before initiating
HAART. Viral HIV-RNA assays were not done at
baseline but at six months after initiating ART and
then every six months thereafter. This parameter
was used to assess response to ARV drugs
(efﬁcacy). The cost of all laboratory assays was
covered by the Thai Ministry of Public Health or
MSF.
Results
Characteristics of the study population
Between February 2002, and November 2003, a
total of 49 children and young adolescents (median
age eight years, range 3–12 years) were prescribed
ARVs using the drug dosage table. Their median
weight was 15kg (range 10–34kg). On initiation of
ART, 28 (57%) children had a CD4 percentage (%)
ranging between 0% and 5%, 19 (39%) had a range
of 5–15%, while in two (4%) patients the CD4%
ranged between 15% and 20%.
The drug dosage table
Table 3 shows the drug dosage table that was
formulated in Thailand.
Acceptability of the drug dosage table among
doctors
A total of 18 doctors which included 14 GPs and
four paediatricians were involved in the study.
Twelve (67%) doctors had treated HIV-positive
children for opportunistic infections including
cotrimoxazole and ﬂuconazone prophylaxis before,
but had no experience prescribing HAART. Six
doctors (including the four paediatricians) had
prescribed ARV drugs before albeit mono or dual
ARV therapy without using a standardized drug
table. All doctors completed the questionnaire.
Seventeen (94%) found the dosage table simple to
understand and practical to use, 17 (94%) felt it
avoided miscalculations in dosage calculations and
15 (83%) felt that it facilitated prescriptions for
children and made them more conﬁdent in
prescribing ARVs. Fifteen (83%) doctors found that
the one page drug dosage table was portable and
convenient. Seventeen doctors wished to continue
using the table. All the six doctors who had
previously prescribed ARVs gave favourable re-
sponses.
Safety and efﬁcacy
Individuals were followed up for a median period
of nine months (range 2–21 months). Four children
who had been very ill on admission had died of
complicated opportunistic infections between one
and six weeks of initiation of HAARTand one child
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children had changed residence and were lost to
follow-up. One child simply refused to continue to
take medication and neither the medical team nor
the care-taker were unable to convince her other-
wise. HAARTwas eventually stopped in this child.
Table 4 shows the frequency and types of
adverse drug reaction side-effects seen in the 49
children and adolescents who were started on ARV.
Three (7%) of 43 individuals on AZT developed
anaemia that required a switch to D4T. There were
two (8%) of 26 individuals who developed a dry
maculopapular rash while on NVP. In one child the
rash was transient and NVP was continued with-
out problems, while in the other in whom it was
persistent for over one month NVP had to be
switched to EFV. One (6%) of 16 children on EFV
developed severe drowsiness and was switched to
NVP. The child improved and continued on NVP.
None of the children required admission to
hospital for management and there were no deaths
that were attributed to drug-related side-effects.
HIV-RNA assays assessed by polymerase chain
reaction were available for 12 children who
completed a median period of seven months on
ART. In 11 of these children, HIV-RNA was below
detectable levels (o400copies/mL). Of these, eight
children were ARV naı ¨ve, of whom ﬁve were
prescribed AZT/3TC/NVP while three had AZT/
3TC/EFV. Three children were ARV experienced
(had received dual or mono ARV therapy) and
were placed on D4T/DDI/NFV.
In one ARV-experienced child, a ﬁrst-line ARV
regimen was wrongly prescribed as the care-giver
did not reveal this history. HIV-RNA levels in this
child were at 54,000 copies at six months. The child
was later changed to a second-line regimen.
There were six children who weighed 12–13kg,
two of whom received half a tablet (100mg) of NVP
twice daily (a relative underdose). All these
children achieved HIV-RNA results below limits
of detection.
Discussion
Scaling-up of ARV treatment in resource-poor
settings will require decentralization and manage-
ment by non-specialist doctors who often have a
high-patient load and are unlikely to have had
prior experience with prescribing ARVs in chil-
dren. Introducing a standardized drug dosage
table helped to alleviate some of the practical
difﬁculties associated with prescribing ARVs for
children in Thailand. Our experience with such a
table has been encouraging for a number of
reasons.
First, the great majority of doctors began to
feel much more conﬁdent with prescribing ARVs
in children and found the table practical, helpful
and convenient. Many of these individuals made
laminated pocket versions on their own, which
they carried around and referred to during clinic
sessions and ward-rounds. The table also became
quickly visible on the desks and walls of con-
sultation rooms within the different district hospi-
tals.
Remarkable interest was also shown during
National seminars and workshops and 1500 copies
were sent on request by post to non-governmental
organizations as well as individual clinicians
countrywide. Based on the positive feed-back
from its use, the Ministry of Health in 2002
incorporated an adapted version of the drug
dosage table within the newest National Antire-
troviral guidelines.
5
Second, GPs in district hospitals in Thailand are
often responsible for 100–200 out-patient consulta-
tions daily, while also being on call for the wards,
for the emergency and delivery rooms. A standard
dosage table avoids the need for calculations and
thus saves precious time for the clinician who has a
high patient load. It also reduces the risk of
miscalculations. There is also the added advantage
that any member of the team of clinicians,
pharmacists, nurses and social workers can cross-
check a given prescription with a glance at the
dosage table and verify that the patient has been
given the correct amount of a particular drug.
Third, preparing and dispensing drugs became
easier for the caretaker as clinicians now took into
consideration realistic divisions of available for-
mulations of tablets.
Finally, the table is safe to use under routine
conditions, judging from the low incidence of
adverse side-effects. This is particularly true with
the most commonly used ARVs. Preliminary
evidence of viral suppression in the albeit small
number of children who completed a median
period of seven months of treatment was also
Table 4 Incidence of adverse drug reactions in children placed on antiretroviral drugs
Drug No. of children Adverse drug reactions Comments
Zidovudine 43 3 (7%) anaemia All switched to stavudine
Didanosine and/or stavudine 12 — No cases of neuropathy or pancreatitis
Nevirapine 26 1 (4%) transient mild rash (grade 1) Nevirapine was continued
1 (4%) persistent moderate (grade 2) rash Switched to efavirenz
No raised transaminase above 100IU/L
Efavirenz 16 1 (6%) severe drowsiness Switched to nevirapine
Nelﬁnavir 7 — No cases of diarrhoea
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efﬁcacy of the doses included in the table.
Although these preliminary ﬁndings related to
safety and response are encouraging, this was an
operational study carried out under routine pro-
gramme conditions. Thus, we did not have a
control group which could be included for compar-
ison on children treated without the help of the
table and using the same drug regimens. Historical
data from Thailand are simply not available since
this is the pioneering experience using HAART in
such a setting.
Our main concern was the unavoidable limita-
tion of the drug dosage table that is linked to its
simpliﬁcation. Fine-tuned or accurate dosing based
on ‘exact body weight’ is not possible as all
individuals in a speciﬁc weight range receive a
ﬁxed dose of drug(s) which may thus appear over-
or under-dosed and could have a potential effect on
the degree of viral suppression. One of the main
‘yard sticks’ for measuring satisfactory treatment
response remains the suppression of viral load to
undetectable levels. We wanted to be sure that, in
our cohort, this was being achieved while using the
recommended drug doses in the standardized
dosage table. Our preliminary evidence shows that
undetectable levels (o400copies/mL) of virus
were achieved in all of the ﬁve children who were
ARV naı ¨ve and in 11 (92%) of the 12 children who
had completed seven months of follow-up. This in
its own right is reassuring in terms of treatment
efﬁcacy and virological suppression when com-
pared with studies conducted under research
settings.
Virological response rates in children are known
to be inferior to those in adults when one considers
the evidence from the limited numbers of pub-
lished studies conducted on albeit small numbers
of children.
11 Two previously published studies
using the D4T/3TC/NVP regimen showed that in
eight and two children, respectively, virological
responses varied from 25% (o400copies/mL)
12 to
50% (o50copies/mL)
13 at six months of follow-up.
The virological response rates
13 in children treated
with a combination of nelﬁnavir and two NRTIs in
16 children varied from 69% (o400copies/mL)
and 44% (o50copies/mL) at 12 months of follow-
up.
14
The issue of trying to achieve accurate dosing in
countries with poor resources even while not using
a drug dosage table is anyway not going to be
realistic as long as syrups remain inaccessible and
tablets and capsules remain restricted to available
adult formulations.
Increasing the availability of more paediatric
drug formulations is likely to enhance simpliﬁca-
tion of ART, which is in turn likely to be associated
with improved adherence.
15,16 Despite the impor-
tance of this issue, large multi-national pharma-
ceutical companies that have a monopoly on
the manufacture of ARV drugs consider develop-
ing countries a poor market for their drugs.
Development of more adapted drug formulations
for children is thus not a priority. There have also
been very limited numbers of research studies
carried out to assess ART drug dosages in children.
This is particularly the case for boosted protease
inhibitors. There is thus an urgent need for
international advocacy on both of these issues.
In Thailand, the Ministry of health (MOH) and
the GPO have became aware of the fact that the
lack of paediatric formulations is an important
barrier to implementing ART in children. The
discussions between the MOH, the GPO and the
different partners on trying to produce a standar-
dized drug dosage table catalysed this awareness.
The production of scored tablets and some paedia-
tric formulations by the GPO were positive spin-
offs of this realization.
The GPO now produces generic syrups and
powders, some of which are 10–30 times cheaper
than the brand name formulations.
17 Generic ARVs
currently manufactured by the GPO include AZT
(10mg/mL), DDI –30 and 60mg, 3TC –10mg/mL,
3TC scored tablets –150mg, D4T capsules –15 and
20mg, D4T – 1 and 5mg/mL, and NVP – 200mg
and NVP syrup – 10mg/mL. Development of a
higher concentration (5mg/mL) of D4T syrup has
been done to reduce the total volume of syrup that
children have to swallow. The GPO is also
developing a ﬁxed-dose combination of AZT
(10mg/mL) and 3TC (6mg/mL) syrup as well
as 3TC (30mg), D4T (7mg) and NVP (50mg) syrup
to facilitate administration and adherence in
children.
In resource-poor settings where paediatric drug
formulations are not accessible and where health
providers have little or no experience with ARVs,
our preliminary experience with a standardized
drug dosage table is that it provides a useful and
safe tool to facilitate prescriptions for children.
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